There are benefits to using Omidria during pediatric cataract surgery, including in infants, according to a study.
“Based on the findings from this study, Omidria is the only FDA-approved product for pediatric use as an agent to prevent intraoperative miosis and prevent postoperative pain,” study co-author M. Edward Wilson, MD, told Ocular Surgery News.
Wilson and colleagues assessed the safety of Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution, Omeros) compared with phenylephrine in children aged 0 to 3 years who were undergoing cataract surgery. The researchers
Uncategorized